EUVIMEDEUVIMED entdecken
Open Access

Current state of nanomedicine drug products: An industry perspective

Jeffrey D Clogston, Willard Foss, David Harris, Hardeep Oberoi, Jiayi Pan, Elaine Pu, Elisa A Torrico Guzmán, Katrin Walter, Scott Brown, Patrick Lim Soo

Journal of Pharmaceutical Sciences · 2024-12 · 113 (12) · 3395-3405

DOI: 10.1016/j.xphs.2024.09.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2024-12. Verfasst von Jeffrey D Clogston und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nanotechnology Characterization Lab, Frederick, MD, USA. Electronic address: clogstonj@mail.nih.gov. Hauptthemen laut MEDLINE: Drug Industry, Nanomedicine. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomedicine drug products have reached an unprecedented high in terms of global commercial acceptance and media exposure with the approvals of the mRNA COVID-19 vaccines in 2021. In this paper, we examine the current state of the art for nanomedicine technologies as applied for pharmaceutical products and compare those trends with results from a recent IQ Consortium industry survey on nanomedicine drug products. We find that 1) industry companies continue to push the envelope in terms of new technologies for characterizing their specific drug products, 2) new analytical technologies continue to be utilized by industry to characterize the increasingly complex nanomedicine drug products and 3) alignment and communication are key between industry and regulatory authorities to better understand the regulatory filings that are being submitted. There are many CMC challenges that a company must overcome to successfully file a nanomedicine drug product. In 2022, the FDA Guidance on Drug Products containing Nanomaterials was published, and it provides a roadmap for submission of a nanomedicine drug product. We propose that our paper serves as a complimentary guide providing knowledge on specific CMC issues such as quality attributes, physicochemical characterization methods, excipients, and stability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryNanomedicineHumansCOVID-19Drug ApprovalNanostructuresUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

ExcipientsNanoparticlesNanotechnologyPhysicochemical characterizationRegulatorySurvey

Autor:innen und Institutionen

  • Nanotechnology Characterization Lab, Frederick, MD, USA. Electronic address: clogstonj@mail.nih.gov.
  • Bristol Myers Squibb, Early Biologics Development, Redwood City, CA, USA.
  • Merck & Co., Inc., Rahway, NJ, 07065, USA.
  • AbbVie Inc., Drug Product Development, North Chicago, IL, USA.
  • Biogen, Technical Development, Cambridge, MA, USA.
  • Bristol Myers Squibb, Drug Product Development, Summit, NJ, USA.

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS
  • National Cancer Institute

Zitieren

APA

Clogston, J. D., Foss, W., Harris, D., Oberoi, H., Pan, J., Pu, E., Guzmán, E. A. T., Walter, K., Brown, S., & Soo, P. L. (2024). Current state of nanomedicine drug products: An industry perspective. Journal of Pharmaceutical Sciences, 113(12), 3395-3405. https://doi.org/10.1016/j.xphs.2024.09.005

Vancouver

Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, et al. Current state of nanomedicine drug products: An industry perspective. Journal of Pharmaceutical Sciences. 2024;113(12):3395-3405. doi:10.1016/j.xphs.2024.09.005

BibTeX
@article{Clogston2024,
  author = {Clogston, Jeffrey D and Foss, Willard and Harris, David and Oberoi, Hardeep and Pan, Jiayi and Pu, Elaine and Guzmán, Elisa A Torrico and Walter, Katrin and Brown, Scott and Soo, Patrick Lim},
  title = {Current state of nanomedicine drug products: An industry perspective},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2024},
  volume = {113},
  number = {12},
  pages = {3395--3405},
  doi = {10.1016/j.xphs.2024.09.005}
}
Kostenlos starten →